Regenerative medicine market growth is revolving around emerging market trends and upgrading of medical platforms related to bioscaffolds and prosthesis. A major market trend is the revolution in medical 3D bio-printing supported by huge investments from key players of regenerative medicine market.
The ongoing crisis in organ and tissue transplantation is driving the market value to new edges over tissue and organ bio printing to create organotypic constructs for regenerative medicine.
Major companies focusing on cell and gene therapy are boosting the regenerative medicine market growth with more than 1,000 clinical trials underway in the first quarter of 2019 and altogether FDA estimates 20 cell and gene therapy approvals each year through 2025.
Ongoing collaborations & acquisitions across the pharmaceutical sectors witnessed the acquisition of smaller regenerative medicine firms by strong market holders. As such Novartis acquired AveXis by investing $8.7 billion in 2018.
Promising players showcasing future regenerative medicine market opportunity includes Novartis, Vericel, Integra, Lifesciences, Mimedx Group, Stryker, Wright Medical, Spark Therapeutics, Osiris Therapeutics, Kite Pharma, and Organogenesis.
On August 6, 2019, Novartis AG, received FDA approval for Zolgensma and FDA support for marketing Zolgensma for patients with spinal muscular atrophy (SMA) less than 2 years of age. On the same page Piqray was approved and launched in the US as the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer.
About Novartis AG
Novartis is among the renowned Swiss Biopharma company, with strong hold in cell and gene therapy. Novartis implements innovative and digital medical technologies with R&D) as the core of the company and central to the Novartis strategy, delivering regenerative medicine solution to more than 750 million people globally.
In 2018, Vericel announced the FDA approval of regenerative medicine products including cartilage cell therapy for knee repair-MACI. As well as, NexoBrid and Epicel product for permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns.
About Vericel Corporation
Vericel Corporation is a leader in regenerative medicine market and the company holds registered trade marks for a cellularized scaffold product and derma treatment products. Vericel Corporation records second quarter product revenues of $26.2 Million in 2019.
In 2018, Integra LifeSciences, announced it has been selected as a primary provider for cellular-based tissue products within Healogics Inc. new iSupply program.
In March, 2019, Integra LifeSciences announced approval of DuraGen dural regeneration matrix in Japan. DuraGen is the first and only non-autologous collagen xenograft approved for use as a dural substitute.
About Integra LifeSciences Holdings Corporation
Integra LifeSciences is a 30 year old global leader in regenerative medicine technologies and is focused on ensuring hospitals and patients receive the best value products ranging from wound care, tissue regenerative therapy, to arthroplasty solutions.